ABUS vs T
Arbutus Biopharma Corp (ABUS) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported T revenue for 2025-12-31 was $125.65B. Net income was $21.95B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. T currently screens at market cap $155.92B and trailing P/E 7.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the ABUS and T stock pages for the full models.
Not investment advice.